Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Pfizer Stock Jumps On Mixed, But 'Marginally Encouraging,' 2025 Outlook

Pfizer stock jumped Tuesday after the pharma giant issued a mixed outlook for 2025. Revenue missed forecasts, while earnings beat some.

Investors Business Daily

AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?

AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock.

Investors Business Daily

More ‘discreet’ Viagra-type drug could soon be available in Britain

US company Viatris has applied for a UK trademark for wafer-like film that dissolves in the mouth

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

"I’d love to see fewer boundaries in the design industry”: a day in the life of Amy Globus

Team's co-founder discusses approaching design with an artist's sensibility.

Creative Bloq

President-Elect Trump Hosts Pharmaceutical Ceos For Dinner At Mar-A-Lago

President-elect Trump's dinner with pharmaceutical executives and healthcare appointees highlights industry collaboration and healthcare challenges.

Top News

Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Despite Pfizer's underperformance relative to the healthcare sector, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments

Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 therapies, amid Q3 growth.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.

MarketBeat

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.

Investors Business Daily

Is Biotech’s Bull Run Over? Examining Election Impacts

The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.

MarketBeat

Pfizer Not Eligible To Recover $75 Million From Settlement With SEC

Judge ruled that Pfizer could not recover $75 million left over from insider trading SEC settlement.

International Business Times

The latest COVID booster will soon be available. Should I get one? Am I eligible?

Australia’s Therapeutic Goods Administration (TGA) has recently approved a new COVID booster. The shot was developed by Pfizer and targets the JN.1 sub-variant of Omicron.

The Conversation

ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

MarketBeat

Thursday's Unusual Options Activity Reveals 3 Promising Long-Term Investments

Thursday's trading session revealed 33 call options with unusually high activity and boasting expiration dates of 365 days or more. Three have emerged as promising long-term investments from this diverse pool of potential opportunities.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Pfizer, Moderna, BioNTech Take A Beating After Trump Taps Kennedy To Head Up HHS

Pfizer stock and other vaccine shares tumbled Friday morning after Trump picked Kennedy to lead the Department of Health and Human Services.

Investors Business Daily

Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot

Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone mineral density loss.

Investors Business Daily

Uber Among Top Profit Beats, But Apple Among The Worst

But Uber and Pfizer were among the 10 biggest beats vs. analyst estimates.

The Guardian - UK

Reasons to be hopeful: five ways science is making the world better

If Trump’s re-election is getting you down, these innovations in medicine and technology should cheer you up

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Don't wait for a holiday surge. Now is a good time to get your flu and COVID-19 vaccines

Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to spread

Barchart

Is This High-Yield Dividend Stock a Buy After Earnings?

This pharmaceutical giant's Q3 numbers came in ahead of Street estimates.

Investors Business Daily

Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO

Amgen is focusing deeply on its efforts to treat obesity, the CFO said Wednesday. Amgen stock rose early Thursday.

Barchart

Are Wall Street Analysts Predicting Pfizer Stock Will Climb or Sink?

Despite Pfizer’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Kiplinger

Stock Market Today: Nasdaq Hits New High Ahead of Alphabet Earnings

The Google parent is one of several mega caps reporting earnings this week, with results due out after Tuesday's close.

Kiplinger

Why Pfizer Stock Is Lower After a Beat-and-Raise Quarter

Pfizer stock is down Tuesday even after the drugmaker reported higher-than-expected Q3 earnings and raised its full-year outlook.

The Independent UK

Hundreds of blood cancer patients to benefit from new Pfizer treatment

Myeloma affects 24,000 people a year in the UK

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.